Image-guided radiation therapy vendor ViewRay reported revenue for the third quarter of 2021 that was nearly double what it was a year ago.
For the quarter (end-September 30), the firm posted revenue of $19.2 million, up 90% compared with $10.1 million in revenue reported during the same period in 2020. The company's net loss for the most recent period was $25.3 million, compared with a net loss of $28.1 million in the third quarter of 2020.
Additionally, ViewRay reported that it received seven new orders for MRIdian systems worth a total of $39.4 million during the third quarter of 2021. During that same period in 2020, the company received four new orders totaling $23.4 million in the third quarter of 2020.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
